

## Freedom of Information Request: Our Reference CTMUHB\_338\_22

### You asked:

**1. How many patients in the last 12 months has the trust treated for metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia (AML)?**

Metastatic Cholangiocarcinoma (CCA) - We can confirm that Cwm Taf University Health Board does not hold the information you require. Cwm Taf residents receive treatment for CCA from the Velindre Cancer Centre, Velindre NHS Trust. Therefore, you will need to redirect your request to Velindre, who provide this service to Cwm Taf residents.

Contact details for Velindre are shown in the following link:

<http://www.velindre-tr.wales.nhs.uk/freedom-of-information-contacts>

Acute myeloid leukaemia (AML) - 15 AML patients were diagnosed in the most recent 12 months from 01/09/2021 to 31/08/2022.

**a. For each of AML and CCA, how many have IDH-1 mutation?**

CCA – as above.

AML – Please see response to Q4.

**b. How many CCA are intrahepatic vs extrahepatic?**

**i. How many of each of these present at 2nd line? How many of these at 2nd line have IDH-1 mutation?**

Please see response to question 1.

**b. For AML, how many patients were not fit for intensive chemotherapy? How many of these AML patients have IDH-1 mutation?**

Please see response to Q4.

AML patients are treated under the Clinical Haematology Team. They have their treatment via our outpatient department/haematology day unit. Patients with AML who are fit for intensive treatment/allogeneic stem cell transplant are referred to and receive their treatment at the University Hospital of Wales (UHW).

**2. How many patients have been treated with pemigatinib (CCA), venetoclax plus azacitidine dual therapy or azacitidine monotherapy (AML)?**

NB: No time period stated; answered with respect to the past 12 months as per Q1.

Pemigatinib (0)

Azacitidine Dual Therapy (2)

Azacitidine Monotherapy (0)

**a. What is the average treatment duration for CCA patients treated with pemigatinib and AML patients treated with azacitadine dual therapy and azacitadine monotherapy? What is the preferred azacitadine product?**

Pemigatinib (n/a)  
Azacitidine Dual Therapy (14 weeks)  
Azacitidine Monotherapy (n/a)

Preferred Azacitidine product is Azacitidine 25mg/mL powder for suspension for injection.

**3. What is the real-world dosing for venetoclax (in combination with a CYP3A4)?**

NB: It is assumed that the question refers to CYP3A4 *inhibitors*.

**a. What is the antifungal of choice for patients treated with venetoclax?**

In AML, posaconazole.

**b. What is the antifungal average treatment duration when used in combination with venetoclax?**

In the two patients we have treated, 14 weeks.

**c) what proportion of patients are treated with an antifungal in combination with venetoclax?**

All.

**In what proportion of patients is the antifungal treatment stopped?**

We do not have a standard policy for this, it is left to clinical judgement.

**In what proportion of these pts is the venetoclax dosage altered following cessation of the antifungal?**

In all patients on withdrawal of the CYP3A4 inhibitor, the dose of venetoclax would be reviewed.

**4. Do you routinely test CCA and AML patients for IDH-1 mutation?**

No.

**a. If so when does the testing take place. E.g. at diagnosis or following 1st line progression? Is this done using NGS panel? Is this done using PCR testing?**

N/A.

**b. What is the average turnaround time for these tests?**

N/A.

**5. Who is responsible for the routine management of patients with CCA and AML?**

**a. Clinical oncologist / medical oncologist / specialist nurse etc?**

CCA patients would be supported by a clinical oncologist (Velindre) and the AMLs by a haematologist.

**6. How many admissions have occurred in the last 12 months for patients with CCA and AML?**

**a. What is their average length of stay?**

**b. How many of these patients were readmissions or readmitted during this time? If readmitted, can you state the main reason?**

For patients diagnosed post 01/08/2021:

	Number of admissions	Number of admissions that were readmissions	Average Length of stay (days)
AML	89	34	12
*CCA	28	12	9

\*CCA patients are treated at Velindre, the local admissions are admissions of patients with CCA (the question does not specify that the admissions is for treatment) so the patients provided in the table above have been admitted with other things or for drains etc.

The reasons for readmission are varied, they include; for procedures/treatment to relieve the symptoms of the cancer, for treatment of symptoms resulting from cancer treatment, for palliative care and a range of unrelated admissions as a result of the age and frailty of the cohort.

We trust that this provides the information that you require. Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below. If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the Information Commissioner at the following address:

- Information Commissioner's Office - Wales  
2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH
- Telephone: 0330 414 6421 / Email: [wales@ico.gsi.gov.uk](mailto:wales@ico.gsi.gov.uk)
- <https://ico.org.uk/>

You should note, however, that the Information Commissioner would normally expect you to have exhausted our internal complaints procedures before dealing with such an application. Further guidance may be found on the Information Commissioner's website [click here](#).

Cwm Taf Morgannwg University Health Board routinely publishes details of all Freedom of Information Act requests received in its disclosure log. The Disclosure Log can be found at <http://cwmtafmorgannwg.wales/foi/disclosure-log/>

Please do not hesitate to contact me if you have any queries.

Yours sincerely

**The Freedom of Information Team /Y Tîm Rhyddid Gwybodaeth**